# Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

> **NCT01155583** · PHASE1,PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** azacitidine
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone
- **OTHER:** DNA methylation analysis
- **OTHER:** gene expression analysis
- **OTHER:** bone marrow aspiration
- **OTHER:** immunohistochemistry staining method
- **OTHER:** reverse transcriptase-polymerase chain reaction
- **OTHER:** flow cytometry

## Key facts

- **NCT ID:** NCT01155583
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2016-05-28
- **Final completion:** 2018-11-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155583, "Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01155583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*